Printer Friendly

Aerie Pharmaceuticals Launches Rocklatan in US and Increase in Rhopressa Medicare Part D Coverage to Approximately 75% of Lives.

M2 PHARMA-May 2, 2019-Aerie Pharmaceuticals Launches Rocklatan in US and Increase in Rhopressa Medicare Part D Coverage to Approximately 75% of Lives

(C)2019 M2 COMMUNICATIONS

- US-based ophthalmic pharmaceutical company Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) has launched Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% into the United States glaucoma market, the company said.

Rocklatan is now with national and regional US pharmaceutical wholesalers, and patients can fill prescriptions for Rocklatan through their local pharmacies across the nation.

Rocklatan has already gained non-preferred brand coverage with payors representing 60% of commercial lives.

Additionally, effective May 1, Medicare Part D preferred tier coverage for Rhopressa (netarsudil ophthalmic solution) 0.02% increased from approximately 40% to 75%.

Commercial coverage for Rhopressa remains at 90% of lives, with 55% of lives in a preferred tier.

Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is a once-daily eye drop that is a fixed-dose combination of latanoprost, the most widely-prescribed prostaglandin analog, and netarsudil, the active ingredient in Rhopressa (netarsudil ophthalmic solution) 0.02%, a first-in-class Rho kinase inhibitor specifically designed to target the trabecular meshwork (the eye's principal drainage pathway).

The diseased trabecular meshwork is considered to be the main cause of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.

Rhopressa works by restoring outflow through the trabecular meshwork, while latanoprost increases fluid outflow through a secondary mechanism known as the uveoscleral pathway.

In clinical trials of Rocklatan, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage.

Rocklatan was approved by the FDA in March 2019.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye.

Aerie's first product, Rhopressa (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the US Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018.

In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 2, 2019
Words:374
Previous Article:Sinovant Sciences' Derazantinib's Clinical Trial Application Approved by the China National Medical Products Administration.
Next Article:Vitrolife wins order for 20 EmbryoScope+ from Chinese clinic.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters